KR101741581B1 - Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food - Google Patents

Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food Download PDF

Info

Publication number
KR101741581B1
KR101741581B1 KR1020150160095A KR20150160095A KR101741581B1 KR 101741581 B1 KR101741581 B1 KR 101741581B1 KR 1020150160095 A KR1020150160095 A KR 1020150160095A KR 20150160095 A KR20150160095 A KR 20150160095A KR 101741581 B1 KR101741581 B1 KR 101741581B1
Authority
KR
South Korea
Prior art keywords
expression level
protein
food
lipid metabolism
pcr
Prior art date
Application number
KR1020150160095A
Other languages
Korean (ko)
Other versions
KR20170056818A (en
Inventor
권오란
김지연
임예니
안영숙
이유진
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Priority to KR1020150160095A priority Critical patent/KR101741581B1/en
Publication of KR20170056818A publication Critical patent/KR20170056818A/en
Application granted granted Critical
Publication of KR101741581B1 publication Critical patent/KR101741581B1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for predicting the antioxidative, antiinflammatory, or lipid metabolism control level of a food through the expression level of a gene and a kit using the same. Specifically, The gene expression level of the antioxidant-related genes, the anti-inflammatory genes, the lipid metabolism-related genes, the hemoglobin-related genes, and the three genes involved in plaque formation and blood coagulation were analyzed by qPCR As a result of confirming that the gene expression of antioxidant (7 kinds), anti-inflammatory (15 kinds) and lipid metabolism (9 kinds) was significantly decreased, And may be useful as a method for predicting lipid metabolism regulation level, anti-inflammatory activity, or lipid metabolism regulation level.

Description

[0001] The present invention relates to a method for predicting the level of antioxidant, anti-inflammation, or lipid metabolism of a food through expression level of a gene,

The present invention relates to a method for predicting antioxidative, antiinflammatory, or lipid metabolism regulation levels of a food through a gene expression level and a kit using the method.

Oxygen is the most abundant element on Earth, accounting for 21% of the dry atmosphere, and our body breathes oxygen to gain energy. However, the ground state triplet oxygen, which is an oxygen that is absolutely necessary for the maintenance of life but is in a stable molecular state, has various physical, chemical and environmental factors such as enzymatic system, reductive metabolism, (H 2 O 2 ), such as superoxide radical (O 2- ), hydroxyl radical (HO ·), and hydrogen peroxide (H 2 O 2 ) free radicals (active oxygen) that are toxic to living organisms that cause lethal oxygen toxicity. Also, our bodies are exposed to numerous oxidative injuries. The representative is active oxygen, or harmful oxygen, which is a substance that can not be found in our body as long as we eat and breathe to maintain life. These active oxygen reacts with cellular components such as lipids, proteins, sugars, and DNA to destroy the cells, thereby causing aging, cancer, brain diseases such as stroke, Parkinson's disease, heart disease, ischemia, atherosclerosis, Rheumatism, autoimmune disease, and the like. In addition, the lipid peroxides produced by the lipid peroxidation reaction may cause various diseases caused by oxidative destruction to the cells, leading to various diseases such as aging.

Antioxidants are the free radicals that cause various diseases such as those that prevent aging and damage to our body due to active oxygen. Antioxidants can be divided into those naturally present in the body and those administered externally. Examples of antioxidants naturally present in the body include superoxide dismutase (SOD), glutathione (Glutathione), ferroxidase ), And there are vitamins E, C, and beta carotene, which are administered externally, and selenium is one of the minerals. Although these antioxidants can be taken as medicines, there is a need to be careful about side effects that can occur when an excessive amount of antioxidants are administered.

Inflammation reaction is a biological defense reaction process to regenerate damage caused by invasion that brings about a fundamental change in a cell or tissue of a living body, and acts as local blood vessels, various tissue cells of body fluid, and immune cells. Normally, the inflammatory reaction induced by external invading bacteria is a defense system to protect the living body. However, when abnormally excessive inflammatory reaction is induced, various diseases appear. These diseases are called inflammatory diseases. The inflammatory disease is a disease in which various inflammatory mediators secreted from target cells activated by external stimuli amplify and maintain the inflammation and threaten the life of the human body. Such diseases include acute inflammation, chronic inflammatory diseases in joints such as rheumatoid arthritis have. Prostaglandins, hydroxy fatty acids, etc. are the key inflammatory mediators that induce these inflammatory diseases. They are caused by cyclooxygenase (COX) and lipoxygenase, which are precursors It is produced from arachidonic acid. However, various acute and chronic inflammatory diseases are gradually increasing in modern people due to westernized diet, lack of exercise and environmental pollution.

In modern society, diverse metabolic diseases such as obesity, diabetes, hypertension and arteriosclerosis are rapidly increasing due to repeated lifestyle such as high calorie diet, lack of exercise, excessive stress such as high fat, high sugar and high salt. In particular, obesity is an energy metabolism abnormality caused by an imbalance between intake energy and consumed energy, which is defined as a state in which excess fat is accumulated in fat cells. The most common cause of obesity is increased body weight or body fat accumulation due to ingestion of food containing high energy or high fat, lack of exercise, or body fat accumulation. Cytologically, obesity is caused by the differentiation of adipocyte and lipid metabolism, Of the world.

It has been reported that obesity increases the risk of severe adult diseases such as hypertension, type 2 diabetes, hypertension, heart disease, stroke, arthritis, arteriosclerosis, and cancer, as well as external problems. Recently, studies on the prevention and treatment of obesity have been actively carried out. These studies mainly focus on inhibition of differentiation of adipocytes, suppression of lipid accumulation in adipocytes, and decomposition of accumulated lipids.

On the other hand, Korean Patent Laid-Open No. 10-2010-0009720 discloses a cDNA microarray chip for diagnosis of inflammatory diseases as a prior art on a method for predicting antioxidant, antiinflammatory, and lipid metabolism levels, and Korean Patent Laid-Open Publication No. 10-2012-0104517 Diagnosis, and monitoring of rheumatoid arthritis. However, no method for predicting antioxidant, antiinflammatory, and lipid metabolism levels of foods using the expression level of the gene of the present invention has been known to date.

Accordingly, the present inventors tried to find a method of predicting antioxidant, anti-inflammatory, or lipid metabolism level after ingesting a food or a single component, and after taking a test food or a control food through a human body experiment, (7 species), anti-inflammatory (15 species), lipid metabolism (9 species) from 14 kinds of antioxidant-related genes, 48 kinds of anti-inflammation related genes and 21 kinds of lipid metabolism related genes. , The present invention provides a method for predicting antioxidant, anti-inflammatory, or lipid metabolism levels of foods through comparison of the expression levels of the genes and a kit using the same The present invention has been completed.

It is an object of the present invention to provide a method for predicting antioxidative, anti-inflammatory, or lipid metabolism levels of food through the degree of gene expression and a kit using the same.

In order to achieve the above object,

1) collecting a biological sample from an individual;

2) administering the test food to the individual and collecting the biological sample;

3) measuring the expression level of the antioxidation-related gene or the expression level of the protein from the sample of step 1) and step 2); And

4) comparing the relative expression level of the antioxidation-related gene or protein of the step 3) with the test sample before and after the test food is compared with the control sample.

In addition,

1) collecting a biological sample from an individual;

2) administering the test food to the individual and collecting the biological sample;

3) measuring the expression level of the anti-inflammation-related gene or the expression level of the protein from the sample of step 1) and step 2); And

4) comparing the relative expression level of the anti-inflammation-related gene or protein of step 3) before and after the test food with the control sample.

In addition,

1) collecting a biological sample from an individual;

2) administering the test food to the individual and collecting the biological sample;

3) measuring the expression level of the lipid metabolism-related gene or the expression level of the protein from the sample of step 1) and step 2); And

4) comparing the relative expression level of the gene or protein involved in the lipid metabolism in the step 3) with the test sample before and after the test food is compared with the control sample.

Also, the present invention provides a kit for predicting the antioxidant ability of a food comprising an agent for measuring mRNA of SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD1, or AGER gene or a protein expression level thereof.

The present invention also provides a method of measuring mRNA or protein expression levels of mRNA of TLR4, TNF-a, IL-6, CCL22, PTGDR, IFNA1, STAT3, BCL6, ITGAL, GRB2, TNFRSF1B, AKT1, BCL2, CRLF1, And a kit for predicting the anti-inflammatory activity of foods containing the agent.

Also provided is a kit for predicting the level of lipid metabolism regulation in a food comprising an agent for measuring the mRNA of SLC27A1, SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, or DGKQ gene or its protein expression level.

In the present invention, the test food or the reference food was consumed through the human body experiment, and the gene expression level of 14 antioxidant-related genes, 48 anti-inflammatory genes and 21 lipid metabolism-related genes was confirmed by qPCR As a result, it was confirmed that gene expression of antioxidants (7 kinds), anti-inflammatory agents (15 kinds) and lipid metabolism (9 kinds) was significantly decreased. Thus, by comparing the expression levels of the genes, Anti-inflammatory, or lipid metabolism levels, and kits using the same.

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows a plan of an experiment for an individual of the present invention. Fig.
FIG. 2 shows genes used in the present invention. FIG.
FIG. 3 is a graph showing changes in expression levels of anti-inflammatory genes. FIG.
FIG. 4 is a graph showing changes in the level of expression of antioxidant-related genes.
FIG. 5 is a graph showing changes in expression levels of genes involved in lipid metabolism. FIG.

Hereinafter, the present invention will be described in detail.

In order to achieve the above object,

1) collecting a biological sample from an individual;

2) administering the test food to the individual and collecting the biological sample;

3) measuring the expression level of the antioxidation-related gene or the expression level of the protein from the sample of step 1) and step 2); And

4) comparing the relative expression level of the antioxidation-related gene or protein of the step 3) with the test sample before and after the test food is compared with the control sample.

The antioxidation-related gene is preferably SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD1, or AGER gene.

In addition,

1) collecting a biological sample from an individual;

2) administering the test food to the individual and collecting the biological sample;

3) measuring the expression level of the anti-inflammation-related gene or the expression level of the protein from the sample of step 1) and step 2); And

4) comparing the relative expression level of the anti-inflammation-related gene or protein of step 3) before and after the test food with the control sample.

Preferably, the anti-inflammation-related gene is SLC27A1, SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, or DGKQ gene.

In addition,

1) collecting a biological sample from an individual;

2) administering the test food to the individual and collecting the biological sample;

3) measuring the expression level of the lipid metabolism-related gene or the expression level of the protein from the sample of step 1) and step 2); And

4) comparing the relative expression level of the gene or protein involved in the lipid metabolism in the step 3) with the test sample before and after the test food is compared with the control sample.

Preferably, the lipid metabolism-related gene is SLC27A1, SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, or DGKQ gene.

In the above method, the biological sample of step 1) includes any one which obtains a sample containing DNA from the test sample. For example, the biological sample is preferably blood, plasma, serum, urine, tissue, cells, organs, bone marrow, saliva, sputum and cerebrospinal fluid, but is not limited thereto.

In addition, the individual in step 1) above is preferably a mammal including a human, a mouse, and a rat, and most preferably a human.

The measurement of the level of expression of the protein may be performed using an immunoassay assay, an immunodot assay, a Luminex assay, an ELISA assay, a protein microarray assay, an immunoassay assay, But is not limited thereto.

In a specific example of the present invention, after taking a test food or a control food through a human body experiment (see FIG. 1), 14 kinds of antioxidant-related genes, 48 kinds of anti-inflammation related genes, (7), anti-inflammatory (15), and lipid metabolism (9) gene expression levels were significantly decreased (see Fig. 2) 3 to 5).

Therefore, the present invention can be useful as a method for predicting antioxidant, anti-inflammatory, or lipid metabolism levels of foods through comparison of the expression levels of the genes and kits using the same.

Also, the present invention provides a kit for predicting the antioxidant ability of a food comprising an agent for measuring mRNA of SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD1, or AGER gene or a protein expression level thereof.

The present invention also provides a method of measuring mRNA or protein expression levels of mRNA of TLR4, TNF-a, IL-6, CCL22, PTGDR, IFNA1, STAT3, BCL6, ITGAL, GRB2, TNFRSF1B, AKT1, BCL2, CRLF1, And a kit for predicting the anti-inflammatory activity of foods containing the agent.

Also provided is a kit for predicting the level of lipid metabolism regulation in a food comprising an agent for measuring the mRNA of SLC27A1, SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, or DGKQ gene or its protein expression level.

The term " measurement of mRNA expression level "in the present invention refers to a method for determining the presence and expression level of mRNAs of antioxidant, antiinflammatory, or lipid metabolism related genes in a biological sample in order to predict levels of antioxidant, antiinflammatory, (RT-PCR), competitive RT-PCR, real-time RT-PCR, and RT-PCR, But are not limited to, RNase protection assay (RPA), Northern blotting, DNA chip, and the like.

In the present invention, " measurement of protein expression level " means the presence and expression level of proteins expressed from antioxidant, anti-inflammatory, or lipid metabolism related genes in biological samples to predict levels of antioxidant, antiinflammatory, Preferably, the amount of the protein can be determined using an antibody that specifically binds to the protein of the gene. Methods for this analysis include Western blot, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket, But are not limited to, immunoelectrophoresis, immunohistochemistry, immunoprecipitation assays, complement fixation assays, fluorescence activated cell sorters (FACS), protein chips, and the like. .

The kit may be any type of kit that can be used for predicting the level of antioxidant, antiinflammatory, or lipid metabolism control of food, but is preferably a kit comprising a reverse transcription-polymerase chain reaction kit, The expression of mRNA or protein in a biological sample can be rapidly and accurately measured by using any one of a kit, an ELISA kit, an immunochromatography kit, a luminex assay, a protein microarray kit, and a DNA chip kit, Of antioxidant, anti-inflammatory, or lipid metabolism. Preferably, the kits for predicting the antioxidant, anti-inflammatory, or lipid metabolism control level of the food may further comprise one or more other component compositions, solutions or devices suitable for the assay method.

Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples.

However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

< Example  1> Selection of objects

The subjects of the present invention were male and female adults aged 30 years or older who were overweight or obese with a body mass index (BMI) of 23-30 kg / m 2 and had a high LDL-cholesterol level (130 mg / dL or more) Gyeonggi province).

Specifically, the procedure proceeded as shown in FIG. 1, and the experiment proceeded to a randomized, double-blind, placebo-controlled food comparative study, and the selected individuals were randomly assigned to the test food group or the control group (FIG. 1). Allocated individuals were fed the test food or control food during the 8-week test period, and the fasting blood of each individual was sampled before (0 week) and after ingestion (8 weeks) As shown in FIG. 2, anti-inflammatory, antioxidant and lipid metabolism-related gene expression analyzes were carried out through the qRT-PCR panel.

The names of the genes shown in Fig. 2 are shown in Tables 1 to 3.

Gene name Full name Gene ID Inflammatory mediators and signal transduction (48 species) TLR2 Toll-like receptor 2 7097 TLR4 Toll-like receptor 4 7099 SOCS3 Suppressor of cytokine signaling 3 9021 SOCS6 Suppressor of cytokine signaling 6 9306 TNF Tumor necrosis factor 7124 IL6 Interleukin 6 (interferon, beta 2) 3569 IL12B Interleukin 12B 3593 IL12A Interleukin 12A 3592 IL1B Interleukin 1, beta 3553 IL8 Interleukin 8 3576 CXCL10 (IP-10) Chemokine (C-X-C motif) ligand 10 3627 CXCL9 (MIG) Chemokine (C-X-C motif) ligand 9 4283 CXCL11 (I-TAC) Chemokine (C-X-C motif) ligand 11 6373 CD80 CD80 molecule 941 CD86 CD86 molecule 942 CD40 CD40 molecule, TNF receptor superfamily member 5 958 PTGDR Prostaglandin D2 receptor (DP) 5729 IFNA1 Interferon, alpha 1 3439 IFNB1 Interferon, beta 1, fibroblast 3456 IRF7 Interferon regulatory factor 7 3665 IRF3 Interferon regulatory factor 3 3661 IFNAR1 Interferon (alpha, beta and omega) receptor 1 3454 CCL22 Chemokine (C-C motif) ligand 22 6367 CCL2 (MCP1) Chemokine (C-C motif) ligand 2 6347 CCL5 (RANTES) Chemokine (C-C motif) ligand 5 6352 CCL3 (MIP-1a) Chemokine (C-C motif) ligand 3 6348 CCL4 (MIP-1b) Chemokine (C-C motif) ligand 4 6351 NFKBIA (IkBa) Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 4792 MIF Macrophage migration inhibitory factor (glycosylation-inhibiting factor) 4282 SELL (CD62L) Selectin L 6402 ITGAL Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide) 3683 CR1 Complement component (3b / 4b) receptor 1 (Knops blood group) 1378 SIRPA (SHPS-1) Signal-regulatory protein alpha 140885 PTPN6 (SHP1) Protein tyrosine phosphatase, non-receptor type 6 5777 GRB2 Growth factor receptor-bound protein 2 2885 ESR1 Estrogen receptor 1 2099 STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) 6774 BCL6 B-cell CLL / lymphoma 6 604 EGFR Epidermal growth factor receptor 1956 TNFRSF1B Tumor necrosis factor receptor superfamily, member 1B 7133 TNFRSF18 Tumor necrosis factor receptor superfamily, member 18 8784 CCR3 Chemokine (C-C motif) receptor 3 1232 CRLF1 Cytokine receptor-like factor 1 9244 LITAF Lipopolysaccharide-induced TNF factor 9516 AKT1 Akt murine thymoma viral oncogene homolog 1 207 BCL2 B-cell CLL / lymphoma 2 596 IL1R1 Interleukin 1 receptor, type I 3554 NOX5 NADPH oxidase 5 79400

Gene name Full name Gene ID Plaque formation and blood clotting (3 species) PEAR1 Platelet endothelial aggregation receptor 1 375033 ICAM-1 Intercellular adhesion molecule 1 3383 VCAM-1 Vascular cell adhesion molecule 1 7412 Antioxidant (14 species) SOD1 Superoxide dismutase 1, soluble 6647 SOD2 Superoxide dismutase 2, mitochondrial 6648 GPX3 Glutathione peroxidase 3 (plasma) 2878 GPX1 Glutathione peroxidase 1 2876 GPX4 Glutathione peroxidase 4 2879 CAT Catalase 847 HMOX1 (HO-1) Heme oxygenase (decycling) 1 3162 NOS2 (iNOS) Nitric oxide synthase 2, inducible 4843 CYBB (NOX2) Cytochrome b-245, beta polypeptide 1536 NFE2L2 Nuclear factor, erythroid 2-like 2 4780 CYBA Cytochrome b-245, alpha polypeptide 1535 NCF1 Neutrophil cytosolic factor 1 653361 TXNRD1 (TrxR) Thioredoxin reductase 1 7296 AGER (RAGE) Advanced glycosylation end product-specific receptor 177

Gene name Full name Gene ID Hematopoietic differentiation (2 species) CCL21 Chemokine (C-C motif) ligand 21 6366 IL4R Interleukin 4 receptor 3566 Lipid metabolism (21 species) DGAT1 Diacylglycerol O-acyltransferase 1 8694 GK Glycerol kinase 2710 LPAR2 (EDG4) Lysophosphatidic acid receptor 2 9170 LDLR Low density lipoprotein receptor 3949 LRP1 Low density lipoprotein receptor-related protein 1 4035 RSAD2 Radical S-adenosyl methionine domain containing 2 91543 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 3156 SLC27A1 Solute carrier family 27 (fatty acid transporter), member 1 376497 SCD Stearoyl-CoA desaturase (delta-9-desaturase) 6319 ACACB Acetyl-CoA carboxylase beta 32 ECI1 Enoyl-CoA delta isomerase 1 1632 HADHA Hydroxyacyl-CoA dehydrogenase / 3-ketoacyl-CoA thiolase / enoyl-CoA hydratase (trifunctional protein), alpha subunit 3030 ACADSB Acyl-CoA dehydrogenase, short / branched chain 36 AGPAT6 1-acylglycerol-3-phosphate O-acyltransferase 6 137964 DGKA Diacylglycerol kinase, alpha 80 kDa 1606 DGKH Diacylglycerol kinase, eta 160851 DGKQ Diacylglycerol kinase, theta 110 kDa 1609 MOGAT3 Monoacylglycerol O-acyltransferase 3 346606 PLB1 Phospholipase B1 151056 PTDSS1 Phosphatidylserine synthase 1 9791 ApoE Apolipoprotein E 348

< Experimental Example  1> qPCR  panel analysis of anti-inflammatory / antioxidant / lipid metabolism related genes

RNA was extracted from venous blood obtained from the individual of Example 1, and cDNA was synthesized and qPCR (quantitative PCR) was performed.

Specifically, whole blood was stored at -80 ° C in PAX gene ™ blood RNA tubes (PreAnalytiX, QIAGEN / BD, Hilden, Germany) and RNA was extracted. The total RNA concentration and the ratio of 260/280 nm were measured using a spectrophotometer (Biospec-nano; Shimadzu Corp., Tokyo, Japan), and the following analysis was performed using only the samples with a ratio of 260/280 of 1.7-2.1 . Then, RNA extracted with a cDNA kit (Bioneer, Daejeon, Korea) was synthesized with cDNA.

Using the cDNA synthesized above, 30 μL of PCR components mixture, 0.6 μL rox dye, 1 μL template, 15 μL 2X Greenstar qPCR master mix, and 13.4 μL NF water (Bioneer, Daejeon, Korea) were added per well to the 96-well PCR analysis was performed with the following Step-One-Plus RT-PCR system (Applied Biosystem Foster City, CA, USA). The PCR conditions were 95 deg. C for 10 min, followed by 95 deg. C for 5 sec, 58 deg. C for 25 sec, and 72 deg. C for 30 sec.

14 antioxidant-related genes, 48 anti-inflammatory genes, 21 lipid metabolism-related genes, 2 hemoglobin-related genes, plaque formation and 3 blood coagulation-related genes were analyzed and then beta-2 The degree of expression was calculated by normalizing the relative amount of mRNA with microglobulin (B2M).

As a result, as shown in Fig. 3 to Fig. 5, in the group to which the test food was fed than the group to which the control food was fed, 15 inflammation-related genes (Fig. 3), 7 oxidative stress- And the expression of nine metabolic genes (FIG. 5) was decreased (FIGS. 3 to 5). The genes whose expression was changed are shown in Table 4 below.

Antioxidant (7 kinds) SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD1, AGER Anti-inflammatory (15 species) IL-6, CCL22, PTGDR, IFNA1, STAT3, BCL6, ITGAL, GRB2, TNFRSF1B, AKT1, BCL2, CRLF1, SELL Lipid metabolism (9 species) SLC27A1, SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, DGKQ Hemocytes (1 species) CCL21 Plaque Formation and Blood Coagulation (Type 1) PEAR1

Claims (9)

IL-6, CCL22, PTGDR, IFNA1, STAT3, BCL6, ITGAL, GRB2, TNFRSF1B, AKT1, BCL2, CRLF1, SELL, SLC27A1, SLC2A, SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD, AGER, TLR4, TNF- A biomarker composition for predicting the metabolic disease prevention effect of a food comprising SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, and DGKQ genes or proteins encoded by the genes.
IL-6, CCL22, PTGDR, IFNA1, STAT3, BCL6, ITGAL, GRB2, TNFRSF1B, AKT1, BCL2, CRLF1, SELL, SLC27A1, SLC2A, SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD, AGER, TLR4, TNF- A kit for predicting the metabolic disease prevention effect of a food comprising an agent for measuring mRNA of mRNA of SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, and DGKQ gene or its protein expression level.
The kit for predicting the metabolic disease prevention effect of food according to claim 2, wherein the metabolic disease is any one selected from the group consisting of obesity, diabetes, hypertension, arteriosclerosis, stroke and arthritis.
The method according to claim 2, wherein the mRNA expression level is selected from the group consisting of RT-PCR, competitive RT-PCR, real-time RT-PCR, Wherein the protein is measured by one of the methods selected from the group consisting of RPA (RNase protection assay), Northern blotting, and DNA chip.
The method according to claim 2, wherein the expression level of the protein is selected from the group consisting of Western blot, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunization (Immunoprecipitation Assay, Complement Fixation Assay, Fluorescence Activated Cell Sorter (FACS), and Protein Chip), which are well known to those of skill in the art, Wherein the method comprises the steps of: (a) determining the amount of the compound of the formula
1) from a biological sample isolated from an individual, SOD2, HMOX1, CYBA, NCF1, CYBB, TXNRD, AGER, TLR4, TNF-a, IL-6, CCL22, PTGDR, IFNA1, STAT3, BCL6, ITGAL, GRB2, TNFRSF1B, AKT1 Measuring the mRNA expression level or protein expression level of the BCL2, CRLF1, SELL, SLC27A1, SCD, MOGAT, APOE, GK, LPAR2, LDLR, ACACB, and DGKQ genes;
2) measuring the mRNA expression level or the protein expression level of the gene described in step 1) from the biological sample separated from the individual after administering the test food to the individual
3) comparing the levels of expression measured in steps 1) and 2) above to predict the metabolic disease prevention effect of the food.
The method according to claim 6, wherein the biological sample is blood, plasma, serum or blood cells.
7. The method of claim 6, wherein the mRNA expression level is selected from the group consisting of RT-PCR, competitive RT-PCR, real-time RT-PCR, RNase protection Wherein the protein is measured by one of the methods selected from the group consisting of RPA (RNase protection assay), Northern blotting, and DNA chip.
7. The method of claim 6, wherein the expression level of the protein is selected from the group consisting of Western blot, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunization (Immunoprecipitation Assay, Complement Fixation Assay, Fluorescence Activated Cell Sorter (FACS), and Protein Chip), which are well known to those of skill in the art, The method comprising the steps of: (a) measuring a concentration of a compound of the formula

KR1020150160095A 2015-11-16 2015-11-16 Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food KR101741581B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150160095A KR101741581B1 (en) 2015-11-16 2015-11-16 Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150160095A KR101741581B1 (en) 2015-11-16 2015-11-16 Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food

Publications (2)

Publication Number Publication Date
KR20170056818A KR20170056818A (en) 2017-05-24
KR101741581B1 true KR101741581B1 (en) 2017-05-30

Family

ID=59051348

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150160095A KR101741581B1 (en) 2015-11-16 2015-11-16 Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food

Country Status (1)

Country Link
KR (1) KR101741581B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020111887A1 (en) * 2018-11-30 2020-06-04 차의과학대학교 산학협력단 Brain-derived vesicle-specific marker and brain disease diagnostic method using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054361A1 (en) 1997-05-26 1998-12-03 Shionogi & Co., Ltd. GENE DIAGNOSIS OF DISEASES WHEREIN TNF-$(g)a PROMOTERS PARTICIPATE
JP2008538177A (en) 2005-03-25 2008-10-16 ノバルティス アクチエンゲゼルシャフト Biomarkers for pharmacogenetic diagnosis of type 2 diabetes
JP2013508687A (en) 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド Biomarkers and methods for measuring and monitoring inflammatory disease activity
KR101620274B1 (en) 2015-08-11 2016-05-11 경북대학교 산학협력단 Composition for diagnosis of obesity and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054361A1 (en) 1997-05-26 1998-12-03 Shionogi & Co., Ltd. GENE DIAGNOSIS OF DISEASES WHEREIN TNF-$(g)a PROMOTERS PARTICIPATE
JP2008538177A (en) 2005-03-25 2008-10-16 ノバルティス アクチエンゲゼルシャフト Biomarkers for pharmacogenetic diagnosis of type 2 diabetes
JP2013508687A (en) 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド Biomarkers and methods for measuring and monitoring inflammatory disease activity
KR101620274B1 (en) 2015-08-11 2016-05-11 경북대학교 산학협력단 Composition for diagnosis of obesity and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Int. J. Cancer: 129, 1467-1476 (2011).
한국식품영양과학회지 34(1), 2005.1, 42-56.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020111887A1 (en) * 2018-11-30 2020-06-04 차의과학대학교 산학협력단 Brain-derived vesicle-specific marker and brain disease diagnostic method using same
KR20200066249A (en) * 2018-11-30 2020-06-09 차의과학대학교 산학협력단 Marker for brain derived vesicles and methods for diagnosing brain disease using the same
KR102337232B1 (en) 2018-11-30 2021-12-09 차의과학대학교 산학협력단 Marker for brain derived vesicles and methods for diagnosing brain disease using the same

Also Published As

Publication number Publication date
KR20170056818A (en) 2017-05-24

Similar Documents

Publication Publication Date Title
Gómez‐Ambrosi et al. Gene expression profile of omental adipose tissue in human obesity
JP6211042B2 (en) Genetic polymorphisms associated with cardiovascular disorders and drug responses, methods for their detection and uses
Tang et al. Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: identification of potential neuroprotective candidates for stroke
Lane et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study
US20120283117A1 (en) Determination of eosinophilic esophagitis
Isoda et al. Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis
Hessner et al. Involvement of eotaxin, eosinophils, and pancreatic predisposition in development of type 1 diabetes mellitus in the BioBreeding rat
Kawaguchi et al. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity
Brune et al. Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer’s disease
Watanabe et al. Genetically determined variations of selenoprotein P are associated with antioxidant, muscular, and lipid biomarkers in response to Brazil nut consumption by patients using statins
Hohda et al. Association study of CD14 polymorphism with myocardial infarction in a Japanese population
Kim et al. Aldo-keto reductase activity after diethylhexyl phthalate exposure in eutopic and ectopic endometrial cells
KR101741581B1 (en) Prediction method for the level of anti-oxidation, anti-inflammation, or lipid metabolism of food
Yoon et al. Endothelial nitric oxide synthase gene is associated with vessel stenosis in Korean population
Saijo et al. Effects of the interaction between interleukin-6− 634C/G polymorphism and smoking on serum C-reactive protein concentrations
CA2440008A1 (en) Rat toxicologically relevant genes and uses thereof
Staňková et al. Polymorphisms rs2167444 and rs508384 in the SCD1 Gene Are Linked with High ApoB-48 Levels and Adverse Profile of Cardiometabolic Risk Factors.
Manav et al. Investigation of macrophage migration inhibitory factors and gene polymorphisms in patients with psoriasis
US20100129790A1 (en) Method for Determining Phospholipidosis
Kuwahara et al. Angiogenin expression in the sera and skin of patients with rheumatic diseases
Joshi Impact of a single nucleotide polymorphism in the CD40 gene and diabetes-associated stress factors on endothelial dysfunction
Higurashi et al. Gene expression profiling of polymorphonuclear leukocytes treated with the culture filtrate of Aspergillus fumigatus and gliotoxin
Asl et al. Association of resistin gene polymorphism with type 2 diabetes in khuzestan province
Falus et al. Unequal expression of complement C4A and C4B genes in rheumatoid synovial cells, human monocytoid and hepatoma-derived cell lines.
Ichiishi et al. Genomic approaches and oxygen radical measurement as biomarker candidates of off-season predictor of pollinosis: a pilot study

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant